KKR agreed to acquire Integer Holdings for $5.7 billion in cash, taking the medical device manufacturer private in one of the largest healthcare equipment transactions this year. The price, which values Integer at roughly 13.2x trailing EBITDA based on consensus estimates, represents KKR's seventh healthcare platform acquisition since 2021.

Integer manufactures batteries, electrodes, and critical components for implantable cardiac devices and neuromodulation systems—components that sit inside pacemakers, defibrillators, and spinal cord stimulators. The company generated $1.52 billion in revenue over the trailing twelve months, with gross margins near 28% and a customer base that includes Medtronic, Boston Scientific, and Abbott. Integer operates 17 facilities across the U.S., Mexico, Switzerland, and Malaysia. KKR's offer price per share was not disclosed in initial reporting, but the enterprise value suggests a premium to Integer's recent trading range, which hovered between $105 and $118 over the past quarter.

The transaction extends KKR's vertical integration strategy in medical devices. The firm already owns stakes in Envision Healthcare, ProAmpac (which supplies medical packaging), and Air Methods, and has been building exposure to the supply chain beneath branded device makers rather than competing at the OEM level. Integer's position as a Tier 1 component supplier gives KKR leverage with the cardiovascular device market, which is expected to grow at a 6.8% CAGR through 2029 according to third-party forecasts. The battery and lead-wire business is particularly sticky—switching costs for device manufacturers are high, and regulatory pathways for component changes add 18 to 24 months of friction.

KKR's thesis likely hinges on margin expansion through procurement scale and manufacturing footprint optimization. Integer has historically reinvested heavily in cleanroom capacity and FDA-compliant tooling, which depressed free cash flow conversion. Under private ownership, KKR can extend capex cycles, consolidate suppliers, and potentially reduce Integer's 17-facility footprint by 2 to 3 plants without sacrificing output. The firm has done this before with surgical supplier Capsugel, which it bought in 2011, optimized, and sold to Lonza for $5.5 billion in 2017. The playbook here appears identical—buy a sub-scale manufacturer with good customers, compress costs, then either hold for yield or sell to a strategic in four to six years.

Allocators should monitor KKR's debt structure for this deal, which will likely involve $2.2 billion to $2.8 billion in leveraged loans given the firm's historical 40-50% equity check on platforms this size. The syndication will reveal pricing: if KKR pays SOFR + 375 bps or higher, it signals tighter leveraged finance markets than the firm anticipated. Watch also for any announced management changes at Integer—KKR typically replaces the CFO within 90 days and brings in a healthcare-focused operating partner. Finally, track Medtronic's and Boston Scientific's next earnings calls for any mention of supplier consolidation or component cost pressures, which would indicate how much of Integer's margin KKR can actually extract.

Integer's stock will likely trade near the takeout price until close, expected in Q4 2025 pending regulatory clearance. The deal requires Hart-Scott-Rodino approval but faces minimal antitrust risk given KKR's limited overlapping exposure in active implantable devices.